My NCBISign In
Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment
Heiner Appel, Louise Janssen, Joachim Listing, René Heydrich, Martin Rudwaleit, Joachim Sieper
Arthritis Res Ther. 2008; 10(5): R125. Published online 2008 October 22. doi: 10.1186/ar2537
PMCID:
PMC2592815
Abstract Full Text PDF–446K

Is Cited by the Following 4 Articles in this Archive:

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
Carrie Wagner, Sudha Visvanathan, Jürgen Braun, Désirée van der Heijde, Atul Deodhar, Benjamin Hsu, Michael Mack, Michael Elashoff, Robert D Inman
Ann Rheum Dis. 2012 May 1; 71(5): 674–680. Published online 2011 October 28. doi: 10.1136/ard.2010.148890
PMCID:
PMC3329231
Abstract Full Text PDF–187K Supplementary Material
Baseline new bone formation does not predict bone loss in ankylosing spondylitis as assessed by quantitative computed tomography (QCT) - 10-year follow-up
Mariusz Korkosz, Jerzy Gąsowski, Piotr Grzanka, Janusz Gorczowski, Wojciech Pluskiewicz, Sławomir Jeka, Tomasz Grodzicki
BMC Musculoskelet Disord. 2011; 12: 121. Published online 2011 May 31. doi: 10.1186/1471-2474-12-121
PMCID:
PMC3118153
Abstract Full Text PDF–1.1M
Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis
Rik JU Lories, Frank P Luyten, Kurt de Vlam
Arthritis Res Ther. 2009; 11(2): 221. Published online 2009 April 27. doi: 10.1186/ar2642
PMCID:
PMC2688182
Abstract Full Text PDF–438K
What do biomarkers tell us about the pathogenesis of ankylosing spondylitis?
Walter P Maksymowych
Arthritis Res Ther. 2009; 11(1): 101. Published online 2009 January 7. doi: 10.1186/ar2565
PMCID:
PMC2688221
Abstract Full Text PDF–40K
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk